RGLS
T. Rowe Price Associates’s Regulus Therapeutics RGLS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-29,597
| Closed | -$52K | – | 3135 |
|
|
2025
Q1 | $52K | Hold |
29,597
| – | – | ﹤0.01% | 2920 |
|
|
2024
Q4 | $47K | Sell |
29,597
-2,121,474
| -99% | -$3.37M | ﹤0.01% | 2944 |
|
|
2024
Q3 | $3.38M | Buy |
2,151,071
+2,130,678
| +10,448% | +$3.35M | ﹤0.01% | 1418 |
|
|
2024
Q2 | $0 | Buy |
+20,393
| New | – | ﹤0.01% | 3012 |
|
|
2022
Q2 | – | Sell |
-184,600
| Closed | -$55K | – | 2998 |
|
|
2022
Q1 | $55K | Hold |
184,600
| – | – | ﹤0.01% | 2907 |
|
|
2021
Q4 | $58K | Buy |
184,600
+146,500
| +385% | +$46K | ﹤0.01% | 2917 |
|
|
2021
Q3 | $26K | Buy |
+38,100
| New | +$26K | ﹤0.01% | 2922 |
|
|
2017
Q1 | – | Sell |
-114,400
| Closed | -$257K | – | 2586 |
|
|
2016
Q4 | $257K | Hold |
114,400
| – | – | ﹤0.01% | 2300 |
|
|
2016
Q3 | $378K | Buy |
114,400
+8,800
| +8% | +$29.1K | ﹤0.01% | 2122 |
|
|
2016
Q2 | $305K | Sell |
105,600
-1,700
| -2% | -$4.91K | ﹤0.01% | 2160 |
|
|
2016
Q1 | $744K | Sell |
107,300
-18,000
| -14% | -$125K | ﹤0.01% | 1811 |
|
|
2015
Q4 | $1.09M | Buy |
125,300
+5,600
| +5% | +$48.8K | ﹤0.01% | 1668 |
|
|
2015
Q3 | $783K | Buy |
119,700
+1,800
| +2% | +$11.8K | ﹤0.01% | 1779 |
|
|
2015
Q2 | $1.29M | Buy |
117,900
+20,700
| +21% | +$227K | ﹤0.01% | 1671 |
|
|
2015
Q1 | $1.65M | Buy |
+97,200
| New | +$1.65M | ﹤0.01% | 1614 |
|
|
2014
Q4 | – | Sell |
-337,567
| Closed | -$2.31M | – | 2559 |
|
|
2014
Q3 | $2.31M | Buy |
337,567
+408
| +0.1% | +$2.79K | ﹤0.01% | 1556 |
|
|
2014
Q2 | $2.71M | Buy |
337,159
+560
| +0.2% | +$4.5K | ﹤0.01% | 1531 |
|
|
2014
Q1 | $3.04M | Sell |
336,599
-2,516
| -0.7% | -$22.7K | ﹤0.01% | 1495 |
|
|
2013
Q4 | $2.51M | Buy |
339,115
+72,525
| +27% | +$536K | ﹤0.01% | 1504 |
|
|
2013
Q3 | $2.51M | Buy |
+266,590
| New | +$2.51M | ﹤0.01% | 1511 |
|